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Macrophage activation unveiled
 
In the early 1960s, George Mackaness showed that macrophages from mice 
infected with intracellular bacteria could launch an indiscriminate attack 
against unrelated bacteria. Thus began an explosion of research on the biology 
of what Mackaness first termed “macrophage activation.”
 
Although Mackaness coined the term
in 1962, the concept of macrophage
activation is a century old. In 1905,
Elie Metchnikoff reported that phago-
cytic mononuclear cells from animals
resistant to certain bacterial infections
were more adept at killing those bacte-
ria (1). But how macrophages became
better killers remained mysterious until
Mackaness embarked on his pioneering
work with the intracellular bacterium
 
Listeria monocytogenes
 
.
 
Macrophages get worked up
 
Resistance to infectious organisms was
long thought to depend primarily on
antibodies that help to lyse pathogens
in the presence of complement and
promote microbe ingestion by phago-
cytic cells. But antibody responses to
intracellular pathogens didn’t always
correlate with the level of protection
against that organism, hinting at the
existence of an antibody-independent
form of antimicrobial resistance.
Mackaness, then an immunologist
at the John Curtin School of Medical
Research in Australia, was interested
in studying one such pathogen: 
 
Myco-
bacterium tuberculosis
 
. But rather than
wrestle with the slow-growing 
 
M. tuber-
culosis
 
, he turned to 
 
L. monocytogenes
 
,
against which mice developed a robust,
antibody-independent resistance.
Mackaness soon discovered that in-
fection with 
 
L. monocytogenes
 
 rendered
the mice temporarily resistant to subse-
quent infection with both 
 
L. monocyto-
genes
 
 and unrelated bacteria. He referred
to this phenomenon as acquired cellular
resistance. Careful analysis of the lesions
in resistant mice led Mackaness to at-
tribute the phenomenon to macro-
phages, which accumulated in the lesions
where they ingested bacteria. When
taken out of resistant mice, these cells
could kill a range of bacteria with
heightened efficiency compared with
macrophages from uninfected mice.
This broad resistance waned over
time, but could be reacquired by chal-
lenging the mice with a second dose of
the original bacteria. This second of-
fense activated the macrophages almost
immediately, but this did not occur if
the mice were challenged with an un-
related organism. Hence, the macro-
phage-dependent resistance appeared
to be antigen-specific in its elicitation
but indiscriminate in its expression.
These seminal results were published in
two articles in 
 
The Journal of Experimental
Medicine
 
 (2, 3).
 
Timing is everything
 
Mackaness noted that the timing of
acquired resistance paralleled the devel-
opment of delayed-type hypersensi-
tivity (DTH), a cell-dependent inflam-
matory reaction of the skin. Based on
this, Mackaness boldly (and propheti-
cally) hypothesized that acquired resis-
tance might be directly dependent on
the hypersensitive state.
His later studies showed that the
transfer of cyclophosphamide-sensitive
spleen cells (now recognized as T
cells) from 
 
Listeria
 
-immune mice si-
multaneously induced protection and
DTH in naive mice. However, the
protection was immunologically spe-
cific; lymphoid cells alone did not
transfer nonspecific cellular resistance.
This required both immune lymphoid
cells and an eliciting dose of the corre-
sponding microbe (4, 5), suggesting
that the macrophages needed to inter-
act directly with the challenge organ-
ism to evoke resistance. Thus, ac-
quired cellular resistance hinged on
the coordinated response of antigen-
specific lymphocytes and nonspecific
macrophages.
 
Demystifying activation
 
This was as far as Mackaness got. “We
still had no idea how a lymphocyte could
communicate a property to a macro-
phage,” says Carl Nathan (Cornell Uni-
versity Weill Medical College, New
York), whose own research on macro-
phage activation was inspired in part by
the observations of Mackaness. Nathan,
then a medical student at Harvard Uni-
versity, soon established that a soluble
product made by antigen-stimulated
lymphocytes could activate macrophages
(6). His later studies identified the T cell–
derived cytokine interferon-
 
 
 
 as the
primary instigator of this activation (7).
“Mackaness was the first to assign
the specificity [of an immune reaction]
to one cell and the execution to an-
other cell,” notes Nathan. His work
also helped pave the way for other
areas of research including cytokine
biology, tumor immunology, and the
biochemistry of macrophage killing.
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